FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200087656> ?p ?o ?g. }

• W4200087656 endingPage "S378" @default.
• W4200087656 startingPage "S377" @default.
• W4200087656 abstract "Abstract Background Neutralizing antibody therapies targeting SARS-CoV-2 have been released for emergency use authorization by the FDA. Little is published on their real-world experience. In this retrospective study we share the results of our early experience on patient outcomes from use of these neutralizing antibodies within a large healthcare system. Methods We retrospectively analyzed results of a healthcare system wide program to pro-actively identify and treat COVID-19 patients with neutralizing antibody therapy. Results The 449 patients identified for SARS-CoV-2 neutralizing antibody therapy during the study period were retrospectively classified as falling in one of the three groups: untreated (199), bamlanivimab (87) and casirivimab/indevimab (125) treated patients (Table 1). Reasons identified patients were not treated most commonly were patient declined (n=74), unable to be contacted (n=36), out of treatment window (n=23), asymptomatic and feeling better (n=21) or did not have transportation (n=9). Bamlanivimab infusion did not reduce emergency room (ER) visits or hospitalization compared to untreated patient within 30-days of follow up (Table 2), and among all patients treated with antibody therapy only treatment with bamlanivimab and non-white race were predictors of need for hospitalization (Table 3). Casirivimab/indevimab did reduce subsequent ER visits or hospitalization within 30 days post-infusion when compared to the untreated group. However, patients treated with either antibody therapy had lower acuity of COVID-19 disease as reflected in need for intensive care unit (ICU) stay, mechanical ventilation or death (Table 2). Table 1. Characteristics of infused vs uninfused patients Table 2. Outcomes in treated vs untreated patients Table 3. Risk factors for ED visits or hospitalization in infused patients Conclusion Either neutralizing antibody therapy appears to markedly reduce acuity of COVID-19 disease even if patients do progress to requiring hospitalization. However, casirivimab/indevimab therapy also decreased ER visits and hospitalization suggesting better efficacy in our experience. Disclosures Christopher Polk, MD, Atea (Research Grant or Support)Gilead (Advisor or Review Panel member, Research Grant or Support)Humanigen (Research Grant or Support)Regeneron (Research Grant or Support) Mindy Sampson, MD, Regeneron (Grant/Research Support)" @default.
• W4200087656 created "2021-12-31" @default.
• W4200087656 creator A5004790988 @default.
• W4200087656 creator A5017916351 @default.
• W4200087656 creator A5020727018 @default.
• W4200087656 creator A5044632429 @default.
• W4200087656 creator A5046669964 @default.
• W4200087656 creator A5069781862 @default.
• W4200087656 creator A5072429482 @default.
• W4200087656 creator A5080040125 @default.
• W4200087656 date "2021-11-01" @default.
• W4200087656 modified "2023-09-27" @default.
• W4200087656 title "550. Bamlanivimab and Casirivimab/Imdevimab Treatment Outcomes: Results from a Large Healthcare System’s Structured Implementation Experience" @default.
• W4200087656 doi "https://doi.org/10.1093/ofid/ofab466.749" @default.
• W4200087656 hasPublicationYear "2021" @default.
• W4200087656 type Work @default.
• W4200087656 citedByCount "0" @default.
• W4200087656 crossrefType "journal-article" @default.
• W4200087656 hasAuthorship W4200087656A5004790988 @default.
• W4200087656 hasAuthorship W4200087656A5017916351 @default.
• W4200087656 hasAuthorship W4200087656A5020727018 @default.
• W4200087656 hasAuthorship W4200087656A5044632429 @default.
• W4200087656 hasAuthorship W4200087656A5046669964 @default.
• W4200087656 hasAuthorship W4200087656A5069781862 @default.
• W4200087656 hasAuthorship W4200087656A5072429482 @default.
• W4200087656 hasAuthorship W4200087656A5080040125 @default.
• W4200087656 hasBestOaLocation W42000876561 @default.
• W4200087656 hasConcept C126322002 @default.
• W4200087656 hasConcept C159654299 @default.
• W4200087656 hasConcept C167135981 @default.
• W4200087656 hasConcept C194828623 @default.
• W4200087656 hasConcept C195910791 @default.
• W4200087656 hasConcept C203014093 @default.
• W4200087656 hasConcept C2776376669 @default.
• W4200087656 hasConcept C2777080012 @default.
• W4200087656 hasConcept C2777910003 @default.
• W4200087656 hasConcept C71924100 @default.
• W4200087656 hasConceptScore W4200087656C126322002 @default.
• W4200087656 hasConceptScore W4200087656C159654299 @default.
• W4200087656 hasConceptScore W4200087656C167135981 @default.
• W4200087656 hasConceptScore W4200087656C194828623 @default.
• W4200087656 hasConceptScore W4200087656C195910791 @default.
• W4200087656 hasConceptScore W4200087656C203014093 @default.
• W4200087656 hasConceptScore W4200087656C2776376669 @default.
• W4200087656 hasConceptScore W4200087656C2777080012 @default.
• W4200087656 hasConceptScore W4200087656C2777910003 @default.
• W4200087656 hasConceptScore W4200087656C71924100 @default.
• W4200087656 hasIssue "Supplement_1" @default.
• W4200087656 hasLocation W42000876561 @default.
• W4200087656 hasLocation W42000876562 @default.
• W4200087656 hasOpenAccess W4200087656 @default.
• W4200087656 hasPrimaryLocation W42000876561 @default.
• W4200087656 hasRelatedWork W2153160359 @default.
• W4200087656 hasRelatedWork W2725902666 @default.
• W4200087656 hasRelatedWork W2784535017 @default.
• W4200087656 hasRelatedWork W2993632815 @default.
• W4200087656 hasRelatedWork W3024249827 @default.
• W4200087656 hasRelatedWork W3146714785 @default.
• W4200087656 hasRelatedWork W3148396094 @default.
• W4200087656 hasRelatedWork W3189248554 @default.
• W4200087656 hasRelatedWork W3204334067 @default.
• W4200087656 hasRelatedWork W4306751403 @default.
• W4200087656 hasVolume "8" @default.
• W4200087656 isParatext "false" @default.
• W4200087656 isRetracted "false" @default.
• W4200087656 workType "article" @default.